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There is a growing recognition of importance of sex in stroke outcome. More women are affected by stroke 
because of their longer life expectancy and have a worse func-
tional outcome and a lower quality of life after stroke com-
pared with men.1–3
In patients with acute stroke, previous research has also 
shown sex to affect outcome after intravenous thromboly-
sis (IVT) treatment; although outcome was similar between 
men and women treated with placebo, outcome was better in 
women after IVT.4 The biological explanation for this differ-
ence remains unclear.
A possible explanation could be the difference in recana-
lization. Women have more cardioembolic strokes, with 
uniform fibrin-rich clots and therefore a higher affinity of 
alteplase, resulting in more frequent, faster, and complete 
recanalization.5–7
Another suggested mechanism could be a difference in 
endogenous fibrinolysis because of differences in sex hor-
mones between men and women. Estrogen has an indirect 
influence on the controlling of the fibrinolytic system, as well 
as a direct neuroprotective activity.8–11 However, there are no 
convincing data to support these hypotheses.
Background and Purpose—Women have a worse outcome after stroke compared with men, although in intravenous 
thrombolysis (IVT)–treated patients, women seem to benefit more. Besides sex differences, age has also a possible effect 
on functional outcome. The interaction of sex on the functional outcome in IVT-treated patients in relation to age remains 
complex. The purpose of this study was to compare outcome after IVT between women and men with regard to age in a 
large multicenter European cohort reflecting daily clinical practice of acute stroke care.
Methods—Data were obtained from IVT registries of 12 European tertiary hospitals. The primary outcome was poor 
functional outcome, defined as a modified Rankin scale score of 3 to 6 at 3 months. We stratified outcome by age in 
decades. Safety measures were symptomatic intracranial hemorrhage and mortality at 3 months.
Results—In this cohort, 9495 patients were treated with IVT, and 4170 (43.9%) were women with a mean age of 71.9 years. 
After adjustments for baseline differences, female sex remained associated with poor functional outcome (odds ratio, 
1.15; 95% confidence interval, 1.02–1.31). There was no association between sex and functional outcome when data were 
stratified by age. Symptomatic intracranial hemorrhage rate was similar in both sexes (adjusted odds ratio, 0.93; 95% 
confidence interval, 0.73–1.19), whereas mortality was lower among women (adjusted odds ratio, 0.83; 95% confidence 
interval, 0.70–0.99).
Conclusions—In this large cohort of IVT-treated patients, women more often had poor functional outcome compared with 
men. This difference was not dependent on age.   (Stroke. 2017;48:699-703. DOI: 10.1161/STROKEAHA.116.014739.)
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Besides the sex differences, some studies suggest an age-
related difference among IVT-treated patients: young patients 
(18–50 years) possibly benefit more from IVT compared with 
older patients (51–80 years).12–15 The interaction of sex on the 
functional outcome in IVT-treated patients in relation to age 
is not clear.
Patients in randomized trials somehow differ from those in 
daily practice, and such an interaction may not be present out-
side of a trial setting.
The aim of this study was to compare outcome after IVT 
between women and men with regard to age in a large mul-
ticenter European cohort reflecting daily clinical practice of 
acute stroke care.
Methods
Study Population, Procedures, and Outcomes
As a joint initiative of 12 European tertiary stroke centers, the 
Thrombolysis in Ischemic Stroke Patients investigators performed a 
large prospective observational clinical cohort study.
All participating centers treated patients with acute ischemic stroke 
with IVT according to the current guidelines (http://eso-stroke.org/
eso-guideline-directory/).
Data from individual consecutive patients were collected using a 
standardized form with predefined variables as is described in previ-
ous studies.16–19 Local study investigators completed the forms using 
prospectively ascertained in-hospital IVT registries. Completed forms 
from all centers were compiled in the coordinating center in Amsterdam, 
where data were pooled and analyzed as described previously.16,17
Each center reported on the period for which they collected data up 
to July 2014. This period was different for each center. The first data 
were collected in June 1995. Patients were excluded if data on sex or 
3-month outcome were missing.
The following baseline characteristics and medical history were 
used: age, initial stroke severity assessed by National Institutes of 
Health Stroke Scale, independency before index stroke, defined as a 
modified Rankin scale (mRS) score of 0 to 2 previous index stroke, 
hypertension, atrial fibrillation, coronary artery disease, hyperlipid-
emia, diabetes mellitus, antithrombotic medication use before stroke, 
current smoking, and stroke-to-needle time. Outcome measures were 
poor functional outcome defined as an mRS score of 3 to 6 at 3 months 
follow-up and ordinal mRS scores. mRS scores were obtained by the 
local center through a telephone interview or by outpatient clinic visit 
with the patient or caregiver, as described in previous research.16–19 
Safety measures were symptomatic intracranial hemorrhage and mor-
tality at 3 months. Symptomatic intracranial hemorrhage was defined 
according to the criteria of the European Cooperative Acute Stroke 
Study II: any hemorrhage with neurological deterioration, indicated 
by a National Institute of Health Stroke Scale score ≥4 than the value 
at baseline or the lowest value within 7 days, or any hemorrhage lead-
ing to death.20
Statistical Analyses
Clinical characteristics were summarized and compared between 
women and men. All values were presented as mean (±SD) or median 
(interquartile range) for continuous variables and counts (percentage) 
for categorical variables. Percentage proportions were calculated by 
dividing the number of events by the total number of patients, exclud-
ing missing or unknown cases. For the comparison of categorical and 
continuous variables, χ2 and Student t tests were used, respectively.
The main analysis was a comparison of poor outcome as a crude 
odds ratio (OR) and the ordinal mRS scores between women and men 
using Mann–Whitney U and χ2 tests, respectively. We additionally 
compared poor outcome between women and men stratified by age 
in decades (<40, 40–49, 50–59, 60–69, 70–79, and ≥80 years). Crude 
comparisons were adjusted for clinical characteristics that signifi-
cantly differed (P<0.05) between women and men in a multivariate 
logistic regression analysis (adjusted OR). Second, mortality and 
symptomatic intracranial hemorrhage rates were compared between 
women and men (crude and adjusted OR).
Results
Demographic and baseline characteristics according to sex are 
presented in Table 1. Of the 9495 patients treated with IVT, 
4170 (43.9%) were women. Compared with men, women 
were older, had more severe strokes, were less often function-
ally independent before index stroke, and had a longer stroke-
to-needle time. Atrial fibrillation and hypertension were more 
prevalent among women, whereas men more often reported 
hyperlipidemia, diabetes mellitus, and coronary artery disease 
and were more often current smokers.
The 3-month outcome was available for 9070 (95.5%) 
patients. Overall, 50% of the women had a poor outcome, com-
pared with 41% among men (mRS score of 3–6: crude OR, 
Table 1. Clinical Characteristics of Women Compared With 
Men
 Women (n=4170) Men (n=5325) P Value
Age, y (SD) 71.9±14.5 67.0±13.2 <0.001*
Median NIHSS on 
admission (IQR)
11 (6–17) 9 (5–16) <0.001†
Previous mRS score of 
0–2 before index stroke, 
n/N (%)
3071/3390 (90.6) 4164/4334 (96.1) <0.001‡
Previous ischemic 
stroke, n/N (%)
631/4150 (15.2) 798/5199 (15.3) 0.847‡
Hypertension, n/N (%) 2888/4162 (69.4) 3420/5210 (65.6) <0.001‡
Atrial fibrillation, n/N (%) 1354/4155 (32.6) 1250/5208 (24.0) <0.001‡
Coronary artery disease, 
n/N (%)
584/4106 (14.2) 1095/5147 (21.3) <0.001‡
Hyperlipidemia, n/N (%) 1597/4138 (38.6) 2263/5199 (43.5) <0.001‡
Diabetes mellitus, n/N (%) 716/4162 (17.2) 1026/5208 (19.7) <0.002‡
Antithrombotics use 
before stroke, n/N (%)
1626/4035 (40.3) 2012/5065 (39.7) 0.597‡
Current smoking, n/N (%) 499/3414 (14.6) 1144/4170 (27.4) <0.001‡
Median stroke-to-needle 
time, min (IQR)
135 (101–178) 140 (105–180)  
Mean stroke-to-needle 
time, min
149.5±63.3 145.8±63.3 <0.009*
  STN <90 min, n (%) 510 (14.1) 719 (16.1)  
  STN 90–180 min, 
n (%)
2293 (63.4) 2819 (63.0)  
  STN 180–270 min, 
n (%)
701 (19.4) 777 (17.4)  
  STN >270 min, n (%) 113 (3.1) 159 (3.6)  
Variables were included in a multivariate regression model if P<0.05. IQR 
indicates interquartile range; mRS, modified Rankin scale; n/N, number of 
patients divided by total of patients excluding missing data; NIHSS, National 
Institutes of Health Stroke Scale; and STN, stroke-to-needle time.
*Students t test.
†Mann–Whitney U test.
‡χ2.
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1.52; 95% confidence interval, 1.40–1.65; Figure 1). Ordinal 
mRS score differed between men and women (P<0.001; 
Figure 1). Women still had more often a poor functional 
outcome after adjustment for age, stroke severity, functional 
independency before index stroke, hypertension, atrial fibril-
lation, coronary artery disease, hyperlipidemia, diabetes mel-
litus, current smoking, and stroke-to-needle time (OR, 1.15; 
95% confidence interval, 1.02–1.31; Table 2). When age was 
stratified per decade and for adjustments, there was no asso-
ciation between sexes and functional outcome. A suggestion 
of a turning point from a poor functional outcome toward a 
good functional outcome among women was at approximately 
the age of 40 years, but it did not reach statistical significance 
(Table 3; Figure 2).
Symptomatic intracranial hemorrhage rates were similar 
between women and men. Whereas about mortality, female 
sex was associated with a higher mortality rate (OR, 1.40; 
95% confidence interval, 1.24–1.57) in crude analysis, but 
markedly, in multivariate analysis, women had a lower mor-
tality rate (OR, 0.83; 95% confidence interval, 0.70–0.99; 
Table 2). The change in mortality rate was mostly determined 
by age and atrial fibrillation.
Discussion
In this large European multicenter cohort study of consecutive 
ischemic stroke patients receiving IVT, women more often 
had a poor functional outcome after IVT than men. This find-
ing was not dependent on age and could not be explained by a 
higher bleeding risk or mortality rate in women.
This study provides evidence for a interaction between sex 
and outcome after IVT: women more often have a worse func-
tional outcome after IVT than men. This is in contrast to what 
has been previously reported.4,21
Conflicting results come from several studies investigating 
the relation between sex and functional outcome after IVT. 
For example, the secondary analysis of the GAIN (Glycine 
Antagonist in Neuroprotection for Patients With Acute 
Stroke) Americas trial showed that female sex was associ-
ated with a worse functional outcome after IVT, which is in 
line with our findings.22 However, in the Safe Implementation 
of Treatments in Stroke-International Stroke Thrombolysis 
Register (SITS-ISTR), sex did not show influence on the 
functional outcome after IVT, though there was a higher 
bleeding risk among men. This could be a possible explana-
tion for the worse functional outcome among men in contrast 
to our study.23 A pooled analysis of randomized IVT trials 
found no appreciable effect of sex on outcome after IVT and 
concluded that women seem to benefit from IVT because of 
the worse functional outcome among women in the placebo-
treated group.4
Figure 1. Univariate analysis of distribu-
tion of modified Rankin scale (mRS) score 
after intravenous thrombolysis in men and 
women (n=9070).
Table 2. Outcome Measures After Intravenous Thrombolysis 
in Women Versus Men
Outcome
Unadjusted OR 
(95% CI)
Adjusted OR  
(95% CI)*
Main outcome measures
  mRS score of 3–6 at 3 mo 1.52 (1.40–1.72) 1.15 (1.02–1.31)
Safety outcome measures
  SICH
ECASS-II
1.01 (0.83–1.22) 0.93 (0.73–1.19)
  Mortality 1.40 (1.24–1.57) 0.83 (0.70–0.99)
CI indicates confidence interval; ECASS II, European Cooperative Acute Stroke 
Study II; mRS, modified Rankin scale; OR, odds ratio; and SICH, symptomatic 
intracerebral hemorrhage.
*Adjusted baseline variables: age, National Institutes of Health Stroke Scale 
on admission, previous mRS score of 0–2 before index stroke, hypertension, 
atrial fibrillation, coronary artery disease, hyperlipidemia, diabetes mellitus, 
current smoking, and stroke-to-needle time.
Table 3. Poor Functional Outcome After Intravenous 
Thrombolysis in Women Versus Men According to Age 
Category
Age 
Group
Women 
(n/N)
Men  
(n/N)
mRS Score of 
3–6 Unadjusted 
OR (95% CI)
mRS Score of 
3–6 Adjusted OR 
(95% CI)*
<40 27/158 30/179 0.95 (0.49–1.83) 0.80 (0.35–1.83)
40–50 66/216 118/393 1.27 (0.82–1.96) 1.55 (0.91–2.63)
50–60 111/378 263/885 1.09 (0.79–1.51) 1.19 (0.82–1.73)
60–70 286/746 466/1309 1.20 (0.94–1.52) 1.17 (0.89–1.54)
70–80 663/1299 687/1533 1.25 (1.04–1.50) 1.04 (0.84–1.30)
>80 890/1242 463/727 1.35 (1.07–1.71) 1.21 (0.92–1.58)
CI indicates confidence interval; mRS, modified Rankin scale; n/N, number of 
patients divided by total of patients excluding missing data; and OR, odds ratio.
*Adjusted baseline variables: National Institutes of Health Stroke Scale on 
admission, previous mRS score of 0–2 before index stroke, hypertension, atrial 
fibrillation, coronary artery disease, hyperlipidemia, diabetes mellitus, current 
smoking, and stroke-to-needle time.
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A possible explanation for the contrasting findings in our 
study could be that patients in randomized control trials tend 
to have less comorbidities, while in the daily practice, frail 
women are the most affected by stroke. And age was not tak-
ing into account in these studies.
With regard to age, we did not find a significant difference 
in functional outcome after IVT between men and women in 
the different age groups.
In contrast to our study, a recent single-center cohort study 
found that women were more likely to have a favorable out-
come; although male sex was associated with a favorable 
outcome in the older age group, women had a better func-
tional outcome in the middle age group compared with men.24 
However, this study was limited by relatively small number of 
patients compared with our cohort and included fewer elderly 
patients.
Interestingly, our study suggests of a turning point from 
good functional outcome to a poor functional outcome around 
the age of 40 years, which suggest a possible benefit from 
IVT in young women. However, because of small numbers 
of patients in this subgroup, this finding lacked statistical 
significance.
In previous publications, there is some evidence that age is 
related to functional outcome in IVT-treated patients: young 
patients (18–50 years) have possibly more benefit from IVT 
compared with older patients (51–80 years) and an increase 
in mortality and lower functional independence with increas-
ing age, with age ranges ≤30, 31 to 40, 41 to 50, and >50 
years.12–15
A possible explanation for the poor functional outcome 
after IVT in women, especially the older women, could be 
the change in endogenous estrogen levels. In animal stud-
ies, changes in estrogen levels were inversely associated with 
the severity of ischemia and brain injury, and the longer the 
animals were estrogen depleted the higher the incidence of 
stroke.25 In humans, studies showed that the sooner the hor-
mone replacement therapy was started after menopause and at 
younger age, the lower was the incidence of vascular events, 
suggesting a neuroprotective effect from higher estrogen lev-
els.26 Thus, with increase of age, the estrogen levels diminish 
in women and thereby decreasing the suggested neuroprotec-
tive effect of estrogen.
Estrogen also has an indirect influence on the alteplase, by 
lowering the level of platelet activator inhibitor 1, a serine pro-
tease inhibitor which decreases the effectiveness of IVT.8–10 
One might suggest that as women’s estrogen levels decline 
during life, the benefit from IVT for women declines with 
increasing age by higher levels of platelet activator inhibitor 1.
Besides biological hormonal status differences, sex aspects 
such as living situation (alone or with spouse), family support, 
and social background also contribute to long-term functional 
outcome and are largely not included in studies on functional 
outcome after stroke.7
Our study has some limitations: this is a retrospective anal-
ysis of prospectively collected data from a joint initiative of 12 
European stroke centers, and the possibility of under-report-
ing might exist. Because of the absence of a comparison group 
lacking IVT, we were not able to study potential differences 
of effectiveness of IVT in a real-life setting. Moreover, there 
were many baseline differences between women and men, 
which we corrected for, but might have resulted in overcor-
rection. Estrogen levels and living situation and social back-
ground were not assessed, which might differ between male 
and female sexes and could influence the functional outcome.
Thus, our key findings must be interpreted with caution and 
must not lead to withholding IVT in the treatment of women 
with acute ischemic stroke.
Summary/Conclusions
In this large European multicenter consecutive, explorative 
cohort study, representing daily clinical practice, women more 
often have a poor functional outcome after IVT compared 
with men. This difference was not dependent on age. More 
research on potential reasons for these findings is required.
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